Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25932041 | 0.86 | L3MBTL1 (0.37) | L3MBTL1MEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL25884613 | 0.82 | L3MBTL1 (0.30) | L3MBTL1 | |
| SCHEMBL23342177 | 0.79 | PIK3CD (0.32) | MEN1KMT2AALDH1A1 | |
| SCHEMBL25900453 | 0.78 | — | — | |
| SCHEMBL23325004 | 0.76 | — | — | |
| SCHEMBL25900450 | 0.72 | CCR1 (0.36) | L3MBTL1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL26184622 | 0.72 | — | — | |
| SCHEMBL23323491 | 0.69 | DRD4 (0.31) | — | |
| SCHEMBL18705029 | 0.68 | HRH3 (0.40) | MEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL23325920 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234929-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-27 | — | — | US | disclosed |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-27 | — | — | US | disclosed |
| US-20230234929-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-27 | — | — | US | disclosed |
| US-11566007-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2023-01-31 | — | — | US | disclosed |
| US-20210130303-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2021-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11566007-B2 | Ras inhibitors | KRAS, NRAS, HRAS | L3MBTL1 3097/4885MEN1 815/4885KMT2A 3685/4885 |
| US-20230234929-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | L3MBTL1 3097/4885MEN1 815/4885KMT2A 3685/4885 |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | KRAS, HRAS, MTOR | L3MBTL1 1005/4885MEN1 2520/4885KMT2A 3021/4885 |
| US-20210130303-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | L3MBTL1 3097/4885MEN1 815/4885KMT2A 3685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.